<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-28T01:55:08Z</responseDate><request verb="GetRecord" identifier="oai:kostu-rdlopen.rawdatalibrary.net:kostu/10497" metadataPrefix="oai_dc">https://kostu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:kostu-rdlopen.rawdatalibrary.net:kostu/10497</identifier><datestamp>2026-10-27T23:53:17Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_kostu_10000</setSpec><setSpec>col_kostu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Uric acid-to-albumin ratio is associated with metabolic syndrome in a large adult cohort</dc:title><dc:creator>Akkas, Nagihan</dc:creator><dc:subject>biomarkers</dc:subject><dc:subject>cardiometabolic risk</dc:subject><dc:subject>metabolic syndrome</dc:subject><dc:subject>UAR</dc:subject><dc:subject>Uric acid-to-albumin ratio</dc:subject><dc:description>Serum uric acid has been linked to metabolic syndrome (MetS), although the relationship has been inconsistent. The uric acid-to-albumin ratio (UAR) has emerged as a novel composite biomarker that indicates the balance between systemic prooxidant burden and antioxidant capacity. This study aimed to evaluate the independent association between UAR and MetS in a large, real-world adult cohort. This cross-sectional study utilized retrospectively collected data from 4,596 adults (mean age: 38.78 ± 9.78 years; 64.6% female). MetS was defined according to the modified National Cholesterol Education Program– Adult Treatment Panel III (NCEP-ATP III) framework, excluding waist circumference due to significant missing data. Consequently, MetS classification was based on the remaining four criteria: triglycerides, HDL cholesterol, blood pressure, and fasting plasma glucose. UAR was calculated as uric acid (mg/dL) divided by albumin (g/L) and was dichotomized by the cohort median (low vs. high UAR). The prevalence of MetS was 7.0% (n = 320). Participants diagnosed with MetS were older and predominantly male compared to those without the condition (45.23 ± 9.93 vs. 38.29 ± 9.60 years; 61.2% vs. 33.4%, respectively; both P0.001). High UAR was more prevalent in the MetS group (70.9% vs. 44.6%, P0.001). Multivariable analysis revealed that age (OR 1.06, 95% CI 1.05–1.07), sex (female vs. male OR 0.43, 95% CI 0.33–0.56), and UAR group (OR 1.89, 95% CI 1.43–2.49) were independently associated with MetS (all P0.001). These findings indicate that UAR is significantly associated with MetS and adverse metabolic features, suggesting a relationship with cardiometabolic risk and reflecting an underlying metabolic imbalance.</dc:description><dc:publisher>Association of Basic Medical Sciences of FBIH</dc:publisher><dc:date>2026</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/kostu/10497</dc:identifier><dc:identifier>https://doi.org/10.17305/bb.2026.14193</dc:identifier><dc:identifier>2831-0896</dc:identifier><dc:language>en</dc:language><dc:relation>Biomolecules and Biomedicine</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://kostu-rdlopen.rawdatalibrary.net/tr/items/kostu/10497</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>